SSA
APLS

Schonfeld Strategic Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$380K – 1854
2023
Q3 		$380K Buy
+10,000
New +$439K ﹤0.01% 1276

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's APLS Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 123,824 shares — an estimated $4.98M sold.

Schonfeld Strategic Advisors first reported a position in APLS in Q2 2018 and held it in 19 quarters. The position peaked at $15M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 123,824 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.98M.
  • Schonfeld Strategic Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 19 quarters.
  • Schonfeld Strategic Advisors's Apellis Pharmaceuticals position peaked at $15M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.